读书笔记丨长三角肺癌之光-中国肺癌原创临床研究阶段汇总
读书笔记丨感恩并传承CTONG-中国肺癌原创临床研究
陆舜教授：沃利替尼有望成为首个代表中国走向全球的肺癌靶向创新药物
齐聚浙江嘉兴，长三角肺癌再续新篇章——浙江省基层肺癌协作组成立
历史回顾丨浙江省肿瘤医院胸部肿瘤青年医师精彩亮相2016WCLC
走进中国科学院大学附属肿瘤医院（浙江省肿瘤医院）I期临床试验病房
中国科学院大学附属肿瘤医院（浙江省肿瘤医院）I期临床试验病房进修人员招聘公告
长三角实体瘤病友交流群系列全面上线
Lancet Respir Med
Lancet Respir Med Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study Shun Lu（2021）
Transl Lung Cancer Res
Transl Lung Cancer Res Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study Shun Lu（2021）
Ann Transl Med （TEINE, CTONG-0904）
Ann Transl Med Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial Shun Lu（2021）
J Thorac Oncol（RATIONALE 304）
J Thorac Oncol Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer (RATIONALE 304)：A randomized phase 3 trial Shun Lu（2021）
J Thorac Oncol
J Thorac Oncol Efficacy and safety of Niraparib as maintenance treatment in patients with extensive-stage small cell lung cancer after first-line chemotherapy：a randomized， double-blind，phase 3 study Shun Lu（2021）
JAMA Oncol（RATIONALE 307）
JAMA Oncol Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer A phase 3 randomized clinical trial Shun Lu（2021）
Lung Cancer
Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Shun Lu (2020)
Clin Cancer Res
Clin Cancer Res Clonal architecture of EGFR mutation predicts the efficacy of EGFR-Tyrosine Kinase Inhitors in advanced NSCLC: a prospective multicenter study (NCT03059641) Shun Lu (2020)
Lung Cancer （FALUCA）
Lung Cancer A phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer-the FALUCA study Shun Lu (2020)
J Clin Oncol
J Clin Oncol Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer Shun Lu (2018)
J Thorac Oncol
J Thorac Oncol Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung-A multicenter, open-label, randomized, phase III trial Shun Lu (2018)
Ann Oncol（East Asia S-1）
Ann Oncol Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) Shun Lu (2017)
J Thorac Oncol
J Thorac Oncol A multicenter, open-label, randomized phase II controlled study of rh-Endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer Shun Lu (2015)
Chin Med J
Chin Med J Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancer Mei-lin Liao (2008)
临床试验-转化研究闭环式研究平台建设
1.基因多平台检测平台搭建（转化研究）
2.样本库平台搭建（转化研究）
3.罕见靶点类器官模型临床前研究平台搭建（临床试验+转化研究）
4.罕见靶点富集互联网医院平台搭建（临床试验+转化研究）
心路历程
心路历程1: 2019.12 长三角肺癌协作组成立
心路历程2: 2020.04 长三角肺癌协作组临床试验招募启动
心路历程3: 2020.07 长三角肺癌协作组青年医师巡讲团成立
心路历程4: 2021.01 长三角肺癌协作组青年博士团队成立
心路历程5: 2021.03 江苏省基层肺癌协作组成立
心路历程6: 2021.04 长三角肺癌基因多平台检测实验室揭牌
心路历程7: 2021.05 浙江省基层肺癌协作组成立
心路历程8：2021.07 长三角肺癌多中心研究样本库建立